Research in the 1940's and 1950's culminated in the development of an inactivated influenza virus vaccine. However, it has only been since the emergence of the Hong Kong variant of A2 influenza in 1968 that reliable laboratory methods for measuring the antigenicity of these vaccines have been available (11) . Since then, the standardized chicken cell agglutination (CCA) test, employing a reference vaccine, has allowed reproducible analysis of the total vaccine hemagglutinin content. Although the CCA test has allowed standardization of total hemagglutinin content, it has not been possible to measure the relative content of the several antigenic components in a polyvalent vaccine preparation.
Immunodiffusion (ID) techniques have been shown to be suitable both for the study of influenza virus subunits and the detection of homologous antibody responses in various animal species including man (1) (2) (3) (6) (7) (8) (9) (10) the sensitivities of these two media were found to be identical, the latter was ultimately adopted. A very indistinct reaction was obtained with Noble agar (Difco), and salt concentrations less than 5.0% or greater than 10.0% were found to be unsatisfactory with these sera.
Optimal serum dilution for ID precipitation and specificity of reactions. Precipitin reactions could be obtained with undiluted to 1:64 to 1: 128 diluted sera; however, by block titration against the homologous vaccine antigens 1: 8 to 1: 16 serum dilutions were found to be the most sensitive. These dilutions were used subsequently throughout the study.
The specificity of the untreated immune chicken sera used for ID was shown by HI tests as outlined in Table 1 . There were no significant differences between untreated and RDEtreated sera when tested by ID (Table 2) . Consequently, untreated sera were generally employed for ID.
Quantitation of antigen content by ID. Based on the results of the 71C reference vaccine, the relative proportions of A2/Aichi/2/68 and B/Mass/3/66 antigens in the bivalent vaccines were determined. The correlation of the theoretical content to the actual determinations of the experimental and commerical vaccines was extremely high. On the basis of these results, commerical vaccine lot no. 4 contained less A2 and more B antigen than the 71C reference and commerical vaccine lots no. 1 to 3. Commercial vaccine lot no. 5 was included in the study because it failed to meet the CCA requirements of the Division of Biologics Standards (DBS). Analysis of these results revealed that it was apparently deficient predominantly in the B components. The sensitivity of the immunoprecipitin test as performed here is in the range of 100 to 150 CCA units per ml.
DISCUSSION
It is generally believed that adequate quantities of the appropriate inactivated influenza virus antigens afford at least some measure of protection against influenza. However, one of the basic problems that has been encountered in the standardization and, therefore, the evaluation of influenza virus vaccines is how to determine the potency of inactivated antigens. The standardized CCA test is both a simple and reliable technique measuring the total hemagglutinin content of these vaccines. However, it previously has not been possible to measure the relative contribution to the total immunizing mass of the several antigenic components of polyvalent vaccines.
In previous studies (3, 7-10) ID techniques have been applied to the study of disrupted influenza A virus subunits. These same workers showed the soluble antigens to be similar for the various influenza A subtypes.
In turkeys, antibody measured by ID with S antigen correlated with the complement-fixation test but not with the HI test (6) . Employing Formalin-inactivated antigens, Beard has shown a correlation between the detection of type-specific influenza A antibodies by a similar ID technique and complement fixation in man and horses (2) and the homologous HI tests in birds (1) .
Although the immune sera employed in this study undoubtedly contain antibody to a number of surface antigens in addition to the hemagglutinin, the use of a reference vaccine of known strain and hemagglutinin composition has allowed the differentiation in a semiquantitative manner between the influenza subtypes. In this study, lipid solvent split hemagglutinin vaccines were not included as they required a different template and assay system possibly because of a difference in the antigen particle size.
A commercial vaccine which failed to meet DBS standards was examined by these methods and was found to be deficient primarily in the B antigen component. It is probable, therefore, that an error was made during the preparation of the bulk vaccine lot. Conceivably, a vaccine could also fail the CCA test because of a dilutional error which would also be apparent by the ID test. It is hoped that by routine application of these techniques, influenza vaccines released for commerical distribution will be assured not only of adequate total hemagglutinin content but also of adequate potency of each of the component strains. In our opinion, application of the ID test as described in this report would serve as an interim measure until improved tests are developed. Certainly, the use of standardized monospecific antisera, pretreatment of vaccines, reproducibility, more precise expression of quantitation and other test parameters require additional investigation.
